Guardant Health, Inc. (NASDAQ:GH – Get Free Report) was the target of a large increase in short interest in August. As of August 15th, there was short interest totalling 9,390,000 shares, an increase of 34.3% from the July 31st total of 6,990,000 shares. Based on an average daily trading volume, of 2,150,000 shares, the short-interest ratio is currently 4.4 days.
Wall Street Analysts Forecast Growth
Several equities research analysts have commented on GH shares. Piper Sandler boosted their target price on shares of Guardant Health from $30.00 to $34.00 and gave the stock an “overweight” rating in a research report on Tuesday, August 13th. Bank of America upped their target price on shares of Guardant Health from $28.00 to $40.00 and gave the stock a “buy” rating in a research report on Thursday, July 18th. The Goldman Sachs Group upped their price target on Guardant Health from $28.00 to $32.00 and gave the stock a “buy” rating in a report on Wednesday, July 17th. UBS Group upped their target price on Guardant Health from $32.00 to $40.00 and gave the company a “buy” rating in a report on Wednesday, August 21st. Finally, BTIG Research boosted their price objective on shares of Guardant Health from $45.00 to $50.00 and gave the stock a “buy” rating in a research report on Tuesday, July 30th. One investment analyst has rated the stock with a hold rating and seventeen have issued a buy rating to the company’s stock. Based on data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus target price of $39.31.
Read Our Latest Stock Analysis on Guardant Health
Institutional Trading of Guardant Health
Guardant Health Stock Down 1.3 %
Shares of NASDAQ:GH opened at $25.58 on Friday. The company has a current ratio of 5.95, a quick ratio of 5.66 and a debt-to-equity ratio of 16.70. The firm has a market cap of $3.13 billion, a price-to-earnings ratio of -6.53 and a beta of 1.13. The stock’s 50-day moving average price is $29.98 and its two-hundred day moving average price is $24.60. Guardant Health has a 12-month low of $15.81 and a 12-month high of $41.06.
Guardant Health (NASDAQ:GH – Get Free Report) last released its earnings results on Wednesday, August 7th. The company reported ($0.84) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.74) by ($0.10). Guardant Health had a negative return on equity of 246.47% and a negative net margin of 76.34%. The company had revenue of $177.24 million during the quarter, compared to analyst estimates of $162.59 million. During the same period in the prior year, the business posted ($0.67) earnings per share. Guardant Health’s revenue was up 29.2% on a year-over-year basis. On average, research analysts forecast that Guardant Health will post -3.31 EPS for the current year.
About Guardant Health
Guardant Health, Inc, a precision oncology company, provides blood and tissue tests, data sets, and analytics in the United States and internationally. The company provides Guardant360; Guardant360 LDT; Guardant360 CDx Test; Guardant360 Response Test; Guardant360 TissueNext Test; GuardantINFINITY Test; GuardantConnect, an integrated software-based solution designed for clinical and biopharmaceutical customers to connect patients tested with assays with actionable alterations with potentially relevant clinical studies; GuardantOMNI Test for advanced stage cancer; and GuardantINFORM, an in-silico research platform for tumor evolution and treatment resistance across various biomarker-driven cancers.
Featured Articles
- Five stocks we like better than Guardant Health
- What is the Australian Securities Exchange (ASX)
- Birkenstock’s Sudden Slide—Why It Might Be Your Next Big Win
- How to Start Investing in Real Estate
- MarketBeat Week in Review – 8/26 – 8/30
- How to Know Which Cryptocurrency to Buy: A Guide for Investors
- Why Dell Can Continue Winning in AI and Beyond
Receive News & Ratings for Guardant Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Guardant Health and related companies with MarketBeat.com's FREE daily email newsletter.